Providing Evidence to Guide Diagnosis

Enhanced sensing and detection
• New tracking threshold for reliable R-wave sensing*
• Classification by episode type
  – Bradycardia
  – Asystole
  – Ventricular Tachyarrhythmia
  – Fast Ventricular Tachyarrhythmia
• Noise reversion and overrange detection
  – Fast Ventricular Tachyarrhythmia
  – Bradycardia
  – Ventricular Tachyarrhythmia
  – Asystole

Ease of use from insertion to follow-up
• Leadless device with slim shape simplifies insertion
• No wires or patches to diagnostic data without an in-office clinic visit
• Designed to improve patient compliance – no wires or patches

Long-term monitoring capabilities
• Implantable for up to three years
• Designed to improve patient compliance – no wires or patches

Long-term monitoring capabilities
• Implantable for up to three years
• Designed to improve patient compliance – no wires or patches

Connexion with evidence to guide diagnosis
• Designed to improve patient compliance – no wires or patches

ECG DATA STORAGE: TOTAL 49.5 MINUTES

Patient Assistant
Captures patient-activated episodes

Patient Activation – 22.5 minutes

Automatic Activation – 27 minutes

Potential Complications
• Potential complications include, but are not limited to, device migration, skin irritation, infection, cutaneous rejection phenomena (including local tissue reaction), device failure, inappropriate sensing, tissue erosion through the skin, rejection of the device or the device itself, etc. Potential complications may adversely affect the performance of the device, tissue or organ function, or may adversely affect the patient’s health or survival. See the manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications. For further information, please call Medtronic at 1 (800) 328-2518 and/or consult Medtronic’s website at www.medtronic.com.

Potential Complications
• Potential complications include, but are not limited to, device migration, skin irritation, infection, cutaneous rejection phenomena (including local tissue reaction), device failure, inappropriate sensing, tissue erosion through the skin, rejection of the device or the device itself, etc. Potential complications may adversely affect the performance of the device, tissue or organ function, or may adversely affect the patient’s health or survival. See the manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications. For further information, please call Medtronic at 1 (800) 328-2518 and/or consult Medtronic’s website at www.medtronic.com.

www.medtronic.com

Medtronic, Inc.
710 Medtronic Parkway
Minneapolis, MN 55432-5604
USA

Tel: (763) 514-4000
Fax: (763) 514-4879

Medtronic USA Inc.
1200 North Loop Blvd 29-200
Eagan, MN 55121-5254

Medtronic International Support (physicians and medical professionals)

ALWAYS ON WATCH
Reveal® DX Insertable Cardiac Monitor (ICM) captures the information you need to make informed decisions about your syncope patients who suffer from infrequent but recurrent episodes. Due to the complex diagnosis of syncope, it’s important to use the monitoring option that can provide clear information. With continuous monitoring for up to three years, Reveal DX overcomes the limitations commonly found with other testing options.

### Always on Watch

Reveal® DX ICM: 9 cc, 15 g, 62 x 19 x 8 mm

### To Reveal What You Can’t See

#### Episode Log

- **Type**: SYMPTOM, FVT, VT, Asystole, Brady
- **Date**: 06-Feb-2008
- **Time**: 14:31
- **Duration**: 14 minutes
- **Rate**: 60 bpm

#### Episode Counters

- **Prior Session**: No Prior Session
- **Last Session**: 06-Nov-2007
- **Device Lifetime**: Since 06-Nov-2007
- **Symptom**: 1
- **FVT**: 0
- **VT**: 0
- **Asystole**: 1
- **Brady**: 1

#### Compare Diagnostic Yields in Unexplained Syncope Patients

<table>
<thead>
<tr>
<th>TEST/PROCEDURE</th>
<th>YIELD*</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECG</td>
<td>2-11%</td>
</tr>
<tr>
<td>Holter Monitoring</td>
<td>2%</td>
</tr>
<tr>
<td>External Loop Recorder</td>
<td>20%</td>
</tr>
<tr>
<td>Reveal DX ICM</td>
<td>43-88%</td>
</tr>
<tr>
<td>Tilt Table Test**</td>
<td>31-87%</td>
</tr>
<tr>
<td>EP Study** without SHD***</td>
<td>11%</td>
</tr>
<tr>
<td>EP Study** with SHD***</td>
<td>49%</td>
</tr>
</tbody>
</table>

*Based on mean diagnosis time of 5.1 months
**Provocative test
***SHD structural or organic heart disease

---

Actual Size

Volume: 9 cc  
Weight: 15 g  
Dimensions: 62 x 19 x 8 mm

TEST/PROCEDURE YIELD* |
ECG | 2-11%  |
Halter Monitoring | 2%    |
External Loop Recorder | 20% |
Reveal DX ICM   | 43-88% |
Tilt Table Test** | 31-87% |
EP Study** without SHD*** | 11% |
EP Study** with SHD*** | 49% |

*Based on mean diagnosis time of 5.1 months
**Provocative test
***SHD structural or organic heart disease

---

Actual Size

Volume: 9 cc  
Weight: 15 g  
Dimensions: 62 x 19 x 8 mm